Edgewise Therapeutics (NASDAQ:EWTX) Shares Break Above 50-Day Moving Average on Analyst Downgrade

Shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX) crossed above its 50-day moving average during trading on Friday after Wall Street Zen upgraded the stock from a sell rating to a hold rating. The stock has a 50-day moving average of $40.86 and traded as high as $45.76. Edgewise Therapeutics shares last traded at $45.04, with a volume of 3,711,351 shares changing hands.

A number of other equities analysts have also issued reports on EWTX. Leerink Partners set a $52.00 target price on Edgewise Therapeutics in a research note on Tuesday, June 16th. The Goldman Sachs Group raised their price objective on Edgewise Therapeutics from $32.00 to $36.00 and gave the stock a “neutral” rating in a research report on Tuesday, August 11th. Oppenheimer started coverage on Edgewise Therapeutics in a report on Thursday, July 9th. They set an “outperform” rating and a $51.00 price target on the stock. HC Wainwright upped their price objective on shares of Edgewise Therapeutics from $45.00 to $57.00 and gave the company a “buy” rating in a research note on Monday, September 21st. Finally, JPMorgan Chase & Co. upped their price objective on shares of Edgewise Therapeutics from $53.00 to $60.00 and gave the stock an “overweight” rating in a research report on Thursday, August 20th. Nine analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, Edgewise Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $52.83.

Insider Buying and Selling

In other Edgewise Therapeutics news, CMO Joanne Donovan sold 6,522 shares of the firm’s stock in a transaction that occurred on Wednesday, August 12th. The shares were sold at an average price of $43.85, for a total value of $285,989.70. Following the sale, the chief marketing officer owned 11,544 shares in the company, valued at approximately $506,204.40. This trade represents a 36.10% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Alan Russell sold 5,901 shares of the business’s stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $43.73, for a total value of $258,050.73. Following the completion of the sale, the insider directly owned 31,466 shares in the company, valued at $1,376,008.18. This represents a 15.79% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders have sold 38,329 shares of company stock valued at $1,675,529. 21.30% of the stock is currently owned by insiders.

Trending Headlines about Edgewise Therapeutics

Here are the key news stories impacting Edgewise Therapeutics this week:

• Positive Sentiment: A report of takeover interest appears to be the main near-term catalyst behind the stock’s rise. The report does not establish that a deal has been agreed or that a transaction will occur. Edgewise Therapeutics gains amid report of takeover interest
• Positive Sentiment: The FDA gave favorable feedback on EDG-7500’s Phase 3 plan following an end-of-Phase 2 meeting. The STRATUS-HCM program is designed to study obstructive and nonobstructive HCM and is on track to begin in Q4 2026, reducing uncertainty around the development path. FDA meeting and Phase 3 update
• Neutral Sentiment: Wedbush cut its price target to $51 from $53 but kept an Outperform rating, leaving its view positive despite the modest reduction. Wedbush lowers EWTX price target
• Neutral Sentiment: Edgewise reported quarterly EPS of $9.65, well above the consensus estimate of a loss of $0.53. The unusually large reported figure may need context to assess its relevance to ongoing operations.
• Negative Sentiment: Put-option purchases were unusually high, with 2,813 contracts traded—279% above typical volume. This may reflect increased hedging or bearish positioning, though options activity alone does not confirm investor expectations.

Institutional Trading of Edgewise Therapeutics

Large investors have recently made changes to their positions in the business. BlackRock Inc. bought a new stake in shares of Edgewise Therapeutics during the 2nd quarter valued at $268,415,000. Jupiter Topco LLC bought a new stake in Edgewise Therapeutics during the second quarter worth about $246,945,000. Janus Henderson Group PLC lifted its stake in shares of Edgewise Therapeutics by 29.5% in the 1st quarter. Janus Henderson Group PLC now owns 5,915,556 shares of the company’s stock valued at $186,289,000 after acquiring an additional 1,348,706 shares during the last quarter. Bank of America Corp DE bought a new position in Edgewise Therapeutics during the second quarter worth $63,312,000. Finally, Dimensional Fund Advisors LP grew its position in Edgewise Therapeutics by 0.5% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,219,717 shares of the company’s stock valued at $38,413,000 after purchasing an additional 6,060 shares during the period.

Edgewise Therapeutics Stock Performance

The business has a 50 day simple moving average of $40.86 and a 200-day simple moving average of $36.54. The stock has a market cap of $4.89 billion, a P/E ratio of 5.50 and a beta of 0.39.

Edgewise Therapeutics (NASDAQ:EWTX) last posted its quarterly earnings data on Wednesday, November 4th. The company reported $9.65 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.53) by $10.18. On average, sell-side analysts predict that Edgewise Therapeutics, Inc. will post -2.09 earnings per share for the current fiscal year.

Edgewise Therapeutics Company Profile

Edgewise Therapeutics, Inc is a clinical-stage biotechnology company focused on developing small-molecule therapies for severe muscle disorders. The company’s research programs target the biology of skeletal and cardiac muscle, with the goal of addressing diseases for which treatment options remain limited.

Edgewise’s lead product candidate is sevasemten (formerly EDG-5506), an oral therapy designed to reduce contraction-induced muscle damage associated with dystrophinopathies, including Duchenne and Becker muscular dystrophy.